The exclusive consoles will be auctioned off, with all proceeds supporting Cure Cancer to continue their remarkable work.
The distinctive design on the consoles draws inspiration from Dr Kulasinghe’s spatial tumour mapping approach developed in collaboration with Akoya Biosciences and Nanostring Technologies, a process that allows medical experts and specialists to identify cellular architecture and areas of that are resistant to treatment for the first time. The tumour mapping can be life-changing for those who are undergoing cancer treatment.
“These groundbreaking realisations of how cells organise and communicate have been captured by these images that are now featured on the Xbox Series X consoles,” said Dr Arutha Kulasinghe.
Related: Newcastle researcher is Cure Cancer’s Researcher of the Year 2024
“With Xbox and Cure Cancer, we’ve been able to further highlight the transformative leaps we’ve achieved in cancer research.”
From today until 30th April, the custom-designed consoles will be on display at the Microsoft Experience Centre at Westfield Sydney, while the auction is running.
“It is truly incredible how this rare moment of scientific breakthrough is beautifully represented through this collaboration with Xbox,” Cure Cancer CEO, Nikki Kinloch.
“It brings much-needed awareness for supporting groundbreaking cancer research to the wider community, which has always been our mission at Cure Cancer.”
“We are extremely proud of Dr Arutha. Being able to see resistance and sensitivity to current generations of cancer therapies at the time of diagnosis is groundbreaking, and it can be life-changing for those who are going through cancer treatment.”
Menchie Khairuddin is a writer Deputy Content Manager at Akolade and content producer for Third Sector News. She is passionate about social affairs specifically in mixed, multicultural heritage and not-for-profit organisations.
Third Sector acknowledges the traditional custodians of the lands where we live, learn and work. We pay our respects to Elders past, present and emerging.